Organon & Co. Shares Outstanding (Cover Page)
Organon & Co. (OGN) had Shares Outstanding (Cover Page) of 262.61 million shares as of 2026-07-24, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Cover Page
dei:EntityCommonStockSharesOutstanding · last filed 2026-07-31
- 2026-07-24: Entity Common Stock, Shares Outstanding 262.61M shares.
- 2026-04-27: Entity Common Stock, Shares Outstanding 262.60M shares.
- 2026-02-17: Entity Common Stock, Shares Outstanding 260.32M shares.
- 2025-11-03: Entity Common Stock, Shares Outstanding 259.98M shares.
| Period end | Entity Common Stock, Shares Outstanding |
|---|---|
| 2026-07-24 | 262.61M shares 10-Q · filed 2026-07-31 |
| 2026-04-27 | 262.60M shares 10-Q · filed 2026-05-04 |
| 2026-02-17 | 260.32M shares 10-K · filed 2026-02-24 |
| 2025-11-03 | 259.98M shares 10-Q · filed 2025-11-10 |
| 2025-07-30 | 259.97M shares 10-Q/A · filed 2025-11-10 |
| 2025-04-25 | 259.96M shares 10-Q/A · filed 2025-11-10 |
| 2025-02-25 | 257.95M shares 10-K/A · filed 2025-11-10 |
| 2024-10-25 | 257.54M shares 10-Q · filed 2024-11-01 |
| 2024-07-30 | 257.47M shares 10-Q · filed 2024-08-07 |
| 2024-04-26 | 257.17M shares 10-Q · filed 2024-05-03 |
| 2024-02-20 | 255.64M shares 10-K · filed 2024-02-26 |
| 2023-10-27 | 255.61M shares 10-Q · filed 2023-11-03 |
| 2023-08-04 | 255.57M shares 10-Q · filed 2023-08-09 |
| 2023-04-28 | 255.06M shares 10-Q · filed 2023-05-05 |
| 2023-02-22 | 254.38M shares 10-K · filed 2023-02-27 |
| 2022-10-30 | 254.36M shares 10-Q · filed 2022-11-04 |
| 2022-08-01 | 254.33M shares 10-Q · filed 2022-08-05 |
| 2022-05-02 | 253.64M shares 10-Q · filed 2022-05-06 |
| 2022-03-14 | 253.64M shares 10-K · filed 2022-03-21 |
| 2021-11-09 | 253.55M shares 10-Q · filed 2021-11-12 |
| 2021-08-11 | 253.55M shares 10-Q · filed 2021-08-16 |
| 2021-06-15 | 253.52M shares 10-Q · filed 2021-06-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |